These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37209424)

  • 1. Efficacy of favipiravir against influenza virus resistant to both baloxavir and neuraminidase inhibitors.
    Kiso M; Yamayoshi S; Kawaoka Y
    J Antimicrob Chemother; 2023 Jul; 78(7):1649-1657. PubMed ID: 37209424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains.
    Checkmahomed L; M'hamdi Z; Carbonneau J; Venable MC; Baz M; Abed Y; Boivin G
    J Infect Dis; 2020 Jan; 221(1):63-70. PubMed ID: 31419295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020.
    Govorkova EA; Takashita E; Daniels RS; Fujisaki S; Presser LD; Patel MC; Huang W; Lackenby A; Nguyen HT; Pereyaslov D; Rattigan A; Brown SK; Samaan M; Subbarao K; Wong S; Wang D; Webby RJ; Yen HL; Zhang W; Meijer A; Gubareva LV
    Antiviral Res; 2022 Apr; 200():105281. PubMed ID: 35292289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model.
    Koszalka P; George A; Dhanasekaran V; Hurt AC; Subbarao K
    mBio; 2022 Aug; 13(4):e0105622. PubMed ID: 35938724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.
    Takashita E; Daniels RS; Fujisaki S; Gregory V; Gubareva LV; Huang W; Hurt AC; Lackenby A; Nguyen HT; Pereyaslov D; Roe M; Samaan M; Subbarao K; Tse H; Wang D; Yen HL; Zhang W; Meijer A
    Antiviral Res; 2020 Mar; 175():104718. PubMed ID: 32004620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022-2023 season.
    Goto T; Kawai N; Bando T; Takasaki Y; Shindo S; Tani N; Chong Y; Ikematsu H
    Antiviral Res; 2024 Apr; 224():105853. PubMed ID: 38430970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: A Japanese multicenter study in the 2019-2020 influenza season.
    Chong Y; Kawai N; Tani N; Bando T; Takasaki Y; Shindo S; Ikematsu H
    Antiviral Res; 2021 Aug; 192():105092. PubMed ID: 34052230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vivo Antiviral Activity of Baloxavir against PA/I38T-Substituted Influenza A Viruses at Clinically Relevant Doses.
    Kuroda T; Fukao K; Yoshida S; Oka R; Baba K; Ando Y; Taniguchi K; Noshi T; Shishido T
    Viruses; 2023 May; 15(5):. PubMed ID: 37243240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid detection of an I38T amino acid substitution in influenza polymerase acidic subunit associated with reduced susceptibility to baloxavir marboxil.
    Nakauchi M; Takashita E; Fujisaki S; Shirakura M; Ogawa R; Morita H; Miura H; Saito S; Watanabe S; Odagiri T; Kageyama T
    Influenza Other Respir Viruses; 2020 Jul; 14(4):436-443. PubMed ID: 32064779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of influenza A(H3N2) viruses with polymerase acidic subunit substitutions after and prior to baloxavir marboxil treatment during the 2022-2023 influenza season in Japan.
    Chon I; Wagatsuma K; Saito R; Tang JW; Isamu S; Suzuki E; Shirahige Y; Kawashima T; Minato M; Kodo N; Masaki H; Hamabata H; Yoshioka S; Ichikawa Y; Sun Y; Li J; Otoguto T; Watanabe H
    Antiviral Res; 2024 Sep; 229():105956. PubMed ID: 38969237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotypic and phenotypic susceptibility of emerging avian influenza A viruses to neuraminidase and cap-dependent endonuclease inhibitors.
    Andreev K; Jones JC; Seiler P; Kandeil A; Webby RJ; Govorkova EA
    Antiviral Res; 2024 Sep; 229():105959. PubMed ID: 38986873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Baloxavir Resistance-Associated Substitutions on Influenza Virus Growth and Drug Susceptibility.
    Hickerson BT; Petrovskaya SN; Dickensheets H; Donnelly RP; Ince WL; Ilyushina NA
    J Virol; 2023 Jul; 97(7):e0015423. PubMed ID: 37404185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of R152K and R368K neuraminidase catalytic substitutions on in vitro properties and virulence of recombinant A(H1N1)pdm09 viruses.
    Tu V; Abed Y; Fage C; Baz M; Boivin G
    Antiviral Res; 2018 Jun; 154():110-115. PubMed ID: 29674164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of cycling probe based real-time PCR methodology for influenza A viruses possessing the PA/I38T amino acid substitution associated with reduced baloxavir susceptibility.
    Osada H; Chon I; Phyu WW; Wagatsuma K; Nagata N; Kawashima T; Sato I; Saito T; Kodo N; Masaki H; Asoh N; Tsuchihashi Y; Shirahige Y; Ono Y; Shimada Y; Hamabata H; Saito K; Saito R
    Antiviral Res; 2021 Apr; 188():105036. PubMed ID: 33577807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice.
    Abed Y; Fage C; Checkmahomed L; Venable MC; Boivin G
    Antiviral Res; 2020 Jul; 179():104807. PubMed ID: 32343991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses.
    Checkmahomed L; Padey B; Pizzorno A; Terrier O; Rosa-Calatrava M; Abed Y; Baz M; Boivin G
    Viruses; 2020 Oct; 12(10):. PubMed ID: 33049959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors.
    Baek YH; Song MS; Lee EY; Kim YI; Kim EH; Park SJ; Park KJ; Kwon HI; Pascua PN; Lim GJ; Kim S; Yoon SW; Kim MH; Webby RJ; Choi YK
    J Virol; 2015 Jan; 89(1):287-99. PubMed ID: 25320319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza A(H1N1)pdm09 virus exhibiting reduced susceptibility to baloxavir due to a PA E23K substitution detected from a child without baloxavir treatment.
    Takashita E; Abe T; Morita H; Nagata S; Fujisaki S; Miura H; Shirakura M; Kishida N; Nakamura K; Kuwahara T; Mitamura K; Ichikawa M; Yamazaki M; Watanabe S; Hasegawa H;
    Antiviral Res; 2020 Aug; 180():104828. PubMed ID: 32574689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Synergistic Effect of Baloxavir and Neuraminidase Inhibitors against Influenza Viruses In Vitro.
    Guo X; Zhao L; Li W; Cao R; Zhong W
    Viruses; 2024 Sep; 16(9):. PubMed ID: 39339943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pleiotropic Effects of Influenza H1, H3, and B Baloxavir-Resistant Substitutions on Replication, Sensitivity to Baloxavir, and Interferon Expression.
    Hickerson BT; Adams SE; Barman S; Miller L; Lugovtsev VY; Webby RJ; Ince WL; Donnelly RP; Ilyushina NA
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0000922. PubMed ID: 35262375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.